Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Acrux ( (AU:ACR) ).
Acrux Limited has reported significant growth in product-based revenue following the successful launch of new products in late 2024 and early 2025. The company raised $3.989 million through a placement and share purchase plan, and secured $1.729 million in short-term funding from Radium Capital. These financial activities, coupled with the positive market reception of their products, position Acrux to achieve its strategic goal of sustaining future product development.
More about Acrux
Acrux Limited is a specialty pharmaceutical company based in Melbourne, Australia, focused on the development of topical pharmaceuticals. The company is known for its portfolio of topical generics, including products like Nitroglycerin Ointment and Dapsone Gel, and is working towards building a sustainable and growing revenue stream through commercialized products.
YTD Price Performance: 33.33%
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $6.02M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue